Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
<h4>Background</h4> <p>Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are...
Auteurs principaux: | Barnes, T, Leeson, V, Paton, C, Costelloe, C, Simon, J, Kiss, N, Osborn, D, Killaspy, H, Craig, T, Lewis, S, Keown, P, Ismail, S, Crawford, M, Baldwin, D, Lewis, G, Geddes, J, Kumar, M, Pathak, R, Taylor, S |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
National Institute for Health Research
2016
|
Documents similaires
-
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
par: Thomas RE Barnes, et autres
Publié: (2016-04-01) -
Long-term antidepressant treatment for negative symptoms in schizophrenia: the actions study
par: Barnes, T, et autres
Publié: (2017) -
Disclosing the potential impact of placebo controls in antidepressant trials
par: Stephanie C. Chen, et autres
Publié: (2015-06-01) -
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness
par: Thomas RE Barnes, et autres
Publié: (2017-09-01) -
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
par: Crawford, A, et autres
Publié: (2014)